Twenty years after Garmon’s death, Idahoans are getting that recognition. This year’s congressional budget includes a one-time payment of $100,000 for downwinders who lived in the states affected by ...
Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...
A next-generation obesity shot from Eli Lilly and Co. helped patients lose almost a quarter of their body weight, potentially ...
Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.
Eli Lilly’s latest weight-loss shot helped patients lose as much as 29 per cent of their body weight in trials, giving ...
Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly the problem ...
Eli Lilly’s latest weight-loss shot helped patients lose as much as 29 per cent of their body weight in trials, giving ...
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study ...
A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...
Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...
Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...
Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback